Radiofrequency Interstitial Tumor Ablation: Dry Electrode

D. Brooke Johnson, Jeffrey A Cadeddu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

With the shift in the treatment of small renal tumors from radical extirpative surgery to nephron-sparing approaches, dry-electrode radiofrequency ablation (RFA) has emerged as one potential modality. This application of RF energy leads to the production of heat within the treatment zone secondary to the native impedance of living tissue. Animal studies and human clinical series have demonstrated that RFA can create controlled, targeted, reproducible, and lethal lesions. Most clinical series have reported promising results, although some authors question the totality of tumor destruction by RFA. With time, the efficacy of RFA, as measured by patient survival, will be determined. Once this is known, RFA may be compared with other therapeutic modalities for small renal tumors to determine its place.

Original languageEnglish (US)
Pages (from-to)557-562
Number of pages6
JournalJournal of Endourology
Volume17
Issue number8
StatePublished - Oct 2003

Fingerprint

Electrodes
Kidney
Neoplasms
Thermogenesis
Nephrons
Electric Impedance
Therapeutics
Survival
Clinical Studies

ASJC Scopus subject areas

  • Urology

Cite this

Radiofrequency Interstitial Tumor Ablation : Dry Electrode. / Johnson, D. Brooke; Cadeddu, Jeffrey A.

In: Journal of Endourology, Vol. 17, No. 8, 10.2003, p. 557-562.

Research output: Contribution to journalArticle

@article{fd2dd2556daa4229b6d7a97f18cc1ea4,
title = "Radiofrequency Interstitial Tumor Ablation: Dry Electrode",
abstract = "With the shift in the treatment of small renal tumors from radical extirpative surgery to nephron-sparing approaches, dry-electrode radiofrequency ablation (RFA) has emerged as one potential modality. This application of RF energy leads to the production of heat within the treatment zone secondary to the native impedance of living tissue. Animal studies and human clinical series have demonstrated that RFA can create controlled, targeted, reproducible, and lethal lesions. Most clinical series have reported promising results, although some authors question the totality of tumor destruction by RFA. With time, the efficacy of RFA, as measured by patient survival, will be determined. Once this is known, RFA may be compared with other therapeutic modalities for small renal tumors to determine its place.",
author = "Johnson, {D. Brooke} and Cadeddu, {Jeffrey A}",
year = "2003",
month = "10",
language = "English (US)",
volume = "17",
pages = "557--562",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Radiofrequency Interstitial Tumor Ablation

T2 - Dry Electrode

AU - Johnson, D. Brooke

AU - Cadeddu, Jeffrey A

PY - 2003/10

Y1 - 2003/10

N2 - With the shift in the treatment of small renal tumors from radical extirpative surgery to nephron-sparing approaches, dry-electrode radiofrequency ablation (RFA) has emerged as one potential modality. This application of RF energy leads to the production of heat within the treatment zone secondary to the native impedance of living tissue. Animal studies and human clinical series have demonstrated that RFA can create controlled, targeted, reproducible, and lethal lesions. Most clinical series have reported promising results, although some authors question the totality of tumor destruction by RFA. With time, the efficacy of RFA, as measured by patient survival, will be determined. Once this is known, RFA may be compared with other therapeutic modalities for small renal tumors to determine its place.

AB - With the shift in the treatment of small renal tumors from radical extirpative surgery to nephron-sparing approaches, dry-electrode radiofrequency ablation (RFA) has emerged as one potential modality. This application of RF energy leads to the production of heat within the treatment zone secondary to the native impedance of living tissue. Animal studies and human clinical series have demonstrated that RFA can create controlled, targeted, reproducible, and lethal lesions. Most clinical series have reported promising results, although some authors question the totality of tumor destruction by RFA. With time, the efficacy of RFA, as measured by patient survival, will be determined. Once this is known, RFA may be compared with other therapeutic modalities for small renal tumors to determine its place.

UR - http://www.scopus.com/inward/record.url?scp=0242330292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242330292&partnerID=8YFLogxK

M3 - Article

C2 - 14622474

AN - SCOPUS:0242330292

VL - 17

SP - 557

EP - 562

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 8

ER -